clinical trial · NCT07583212
Phase I Study of HRS-1635 in B-cell Malignancies
Chengdu Suncadia Medicine Co., Ltd.·phase1·recruiting·n = 180
B-cell MalignancyHRS-1635
brief summary
The study is being conducted to evaluate the safety and tolerability of HRS-1635. To observe the Dose-Limiting Toxicity (DLT) , explore the Maximum Tolerated Dose (MTD, if possible) and the Recommended Phase 2 Dose (RP2D). This study also preliminarily evaluated the efficacy of HRS-1635 in participants with B-cell malignancy.
started
Jun 30, 2026
primary completion
Oct 1, 2028
completion
Dec 1, 2029
last updated
Jul 13, 2026
official title
An Open-Label, Multicenter Phase I Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-1635 in Patients With B-Cell Malignancies.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol